Gallmeier et al. saw similar results in CD133+ colon CSCs where CD133+ colon CSCs appeared to be more resistant to DNA interstrands crosslinking (ICL) agents such as cisplatin than CD133- colon cancer cells [96]. Here, PROM1 is linked to colonic neoplasm.